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1510Objectives: Patients requiring extracorporeal cardiorespiratory support during lung transplantation can be
treated with conventional cardiopulmonary bypass (CPB) or venoarterial extracorporeal membrane oxygenation
(ECMO). In a retrospective analysis, we compared the postoperative course and outcomes of patients treated
using these approaches.
Methods: Between August 2008 and September 2011, 92 consecutive patients underwent lung transplantation
with extracorporeal support (CPB group, n ¼ 46; and, since February 2010, ECMO group, n ¼ 46) at our in-
stitution. We evaluated survival, secondary organ failure, bleeding complications, and the need for blood and
platelet transfusions in these 2 patient populations.
Results: Intraoperatively, the CPB group required more packed red blood cell transfusions (12 11 vs 7 9 U;
P¼ .01) and platelet concentrates (2.5 1.6 vs 1.5 1 U; P<.01) than the ECMO group. In-hospital mortality
(39% vs 13%; P ¼ .004), the need for hemodialysis (48% vs 13%; P<.01), and new postoperative ECMO
support (26% vs 4%; P<.01) were greater in the CPB group than in the ECMO group, respectively. After pro-
pensity score analysis, multivariate analysis identified retransplantation (odds ratio, 7; 95% confidence interval,
1-43; P ¼ .034) and transplantation with CPB support (odds ratio, 4.9; 95% confidence interval, 1.2-20;
P ¼ .026) as independent risk factors for in-hospital mortality. The survival rate at 3, 9, and 12 months was
70%, 59%, and 56% in the CPB group and 87%, 81%, and 81% in the ECMO group (P ¼ .004).
Conclusions: Intraoperative ECMO allows for better periprocedural management and reduced postoperative
complications and confers a survival benefit compared with CPB, mainly because of lower in-hospital mortality.
It is now the standard of care in our lung transplantation program. (J Thorac Cardiovasc Surg 2012;144:1510-6)Cardiopulmonary bypass (CPB) is currently the standard
method for intraoperative support of hemodynamics and re-
spiratory function in lung transplantation.1 However, its use
could be associated with a greater intra- and postoperative
risk of bleeding owing to full heparinization and a greater
incidence of primary graft dysfunction (PGD) from the con-
sequences of the systemic inflammatory response.2-5
Extracorporeal membrane oxygenation (ECMO) might
present as an alternative to CPB. The benefits of preopera-
tive ECMO support as a bridge to transplantation6-8 ande Department of Cardiothoracic, Transplant, and Vascular Surgerya and
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The Journal of Thoracic and Cardiovascular Surpostoperative ECMO support as rescue therapy for
patients with PGD9,10 have been widely demonstrated.
Recently, the use of ECMO has also been extended to
intraoperative support.11-13 Lower heparin doses, the lack
of a venous reservoir, and additional suction lines with
their air–blood interface could reduce the complications
associated with CPB. Moreover, ECMO is more versatile
owing to the possibility of prolonging hemodynamic and
respiratory support, allowing better postoperative
hemodynamic and respiratory management in patients at
high risk of developing PGD.
With these considerations, since the beginning of 2010,
we have changed our routine intraoperative protocol from
CPB to venoarterial ECMO. In the present study, we com-
pared the outcomes of patients who underwent transplanta-
tion on CPB with the outcomes of those who underwent
transplantation on venoarterial ECMO support.METHODS
Patients
Between August 2008 and September 2011, 319 patients underwent
lung transplantation at our institution. Of these 319 patients, 211 (66%) un-
derwent transplantation off-pump, 10 (3%) with venovenous ECMOgery c December 2012
Abbreviations and Acronyms
COPD ¼ chronic obstructive pulmonary disease
CPB ¼ cardiopulmonary bypass
ECMO ¼ extracorporeal membrane oxygenation
ICU ¼ intensive care unit
iLA ¼ interventional lung assistance with the
NovaLung
PGD ¼ primary graft dysfunction
PRBC ¼ packed red blood cell
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Xsupport; 46 (14%) with CPB support (CPB group); and 52 (16%) with ve-
noarterial ECMO support (ECMO group). Of the ECMO group, 6 patients
who underwent transplantation before February 2010 were excluded from
the present study. Before February 2010, CPB was our standard supporting
technique, and these 6 ECMO patients might have represented a subgroup
selected because of potentially confounding variables. No statistically sig-
nificant difference was seen in the pre- and postoperative morbidity or mor-
tality among the ECMO patients transplanted before and after February
2010. The records of the 46 CPB and 46 ECMO patients were retrospec-
tively reviewed. The pre-, intra-, and postoperative and follow-up results
between the CPB and ECMO groups were compared. Follow-up ended
on November 30, 2011 and was 100% complete.
Pulmonary hypertension as the indication for transplantation included
patients with idiopathic pulmonary hypertension, chronic pulmonary em-
bolism, pulmonary veno-occlusive disease, congenital heart disease with
Eisenmenger disease, and systemic scleroderma. The risk of cytomegalovi-
rus infection was defined as low, if both donor and recipient were negative
for anticytomegalovirus IgG antibodies or intermediate in donor-positive/
recipient-positive or donor-negative/recipient-positive settings. The risk
was considered high in the donor-positive/recipient-negative setting. Ur-
gency listing status, according to the Eurotransplant criteria, and PGD
scores at 24 hours, according to the guidelines of the International Society
for Heart and Lung Transplantation Working Group on PGD,14 were re-
corded. If intraoperative ECMO support was directly extended postopera-
tively, the patients were classified as requiring postoperative ECMO
support. However, patients who had been intraoperatively weaned from
CPB or ECMO but thereafter required new ECMO or interventional lung
assistance with the NovaLung (iLA; NovaLung GmbH, Hechingen, Ger-
many)were classified as requiring secondaryECMO/iLA implantation. Re-
jection was defined as the need for at least 1 steroid pulse therapy in the
presence of unexplained worsening of lung function and gas exchange
and an increase in inflammatory parameters. The mean postoperative dura-
tion of mechanical ventilation and the mean intensive care unit (ICU) stay
were calculated after censoring the patients who had died early (<30 days).
The hospital ethical committee approved the present retrospective study
and waived the need for patient consent.
CPB and ECMO Implant Techniques
CPB was instituted by cannulating the ascending aorta or common fem-
oral artery and, for venous access, the right atrium or femoral vein. Before
cannulation, 400 IU heparin/kg body weight was administered. The target
activated clotting time during CPB was longer than 400 seconds. After
weaning from CPB, protamine was given to antagonize the heparin. The
CPB system consisted of the (1) St€ockert S III roller pump (St€ockert, Mu-
nich, Germany); (2) Apex (Sorin Biomedica, Saluggia, Italy), Capiox
(Terumo Cardiovascular Systems Corp, Ann Arbor, Mich), or the Trillium
Affinity (Medtronic Inc, Minneapolis, Minn) oxygenators (membrane sur-
face area, 2.0, 0.5, and 2.5 m2, respectively); and (3) Medos venous reser-
voir and heparin-coated tubing system (Medos AG, Stolberg, Germany).
The priming volume was usually 1400 mL.The Journal of Thoracic and CarSince February 2010, ECMO has been used during lung transplantation
instead of CPB. After a single bolus of 5000 IU of unfractionated heparin,
ECMOwas instituted by percutaneous cannulation of the common femoral
vein and artery, with a 20F to 24F FemTrak venous cannula (Edwards Life-
sciences, Irvine, Calif) and a 15F to 17F NovaPort arterial cannula (Nova-
Lung GmbH). In patients in whom ECMO support had been planned to be
continued postoperatively, an additional 6F introducer sheath (Cordis Corp,
Miami, Fla) was inserted into the femoral artery distal from the NovaLung
cannula and connected to the arterial branch of the ECMO circuit for ante-
grade leg perfusion. The ECMO system consisted of a Maquet Rotaflow
centrifugal pump and PLS Set with the Quadrox polymethylpentene mem-
brane oxygenator (membrane oxygenator area, 1.8 m2; Maquet Cardiopul-
monary AG, Hirrlingen, Germany). The priming volume was usually 800
mL. A half dose of protamine (2500 IU) was given to antagonize heparin
after intraoperative ECMOweaning. In those patients in whomECMO sup-
port was extended postoperatively, neither protamine nor additional hepa-
rin was administered for a maximum of 48 hours after surgery. Thereafter,
the activated clotting timewasmaintained between 160 and 180 seconds by
continuous infusion of unfractionated heparin.
Statistical Analysis
Data were collected and analyzed retrospectively. SPSS, version 20.0
(SPSS, Chicago, Ill) was used to perform the data analysis. The primary
endpoint was in-hospital mortality, and the secondary endpoint was postop-
erative morbidity. Categorical and continuous variables are summarized as
percentages and mean standard deviation, respectively. The independent
samples Student t test or the nonparametric Mann-Whitney U-test and the
c2 test or Fisher’s exact test were used for groupwise comparisons of con-
tinuous and categorical variables, respectively, and to find the preoperative
univariate associations with the primary endpoint. The P values were 2-
tailed. For a subset of 75 patients with complete data sets, propensity
matching was used to provide a more valid comparison between groups.
Propensity scores representing the estimated probabilities of patients re-
ceiving either CPB or ECMO were developed using 13 observed baseline
preoperative covariates in a logistic regression model with intraoperative
support type (CPB vs ECMO) as the dependent variable (female gender,
chronic renal failure, listing grade, cytomegalovirus risk, pulmonary fibro-
sis, pulmonary hypertension, retransplantation, age at transplantation, sys-
tolic pulmonary pressure, forced expiratory volume in 1 second, forced
vital capacity in 1 second [percentage of predicted], preoperative ECMO
implant, and preoperative oxygen partial pressure). After propensity
matching, multivariate analysis, using a forward stepwise logistic regres-
sionmodel, was performed to identify the preoperative independent predic-
tors of in-hospital mortality. The model was constructed to include the
preoperative risk factors with univariate P values< .2. Model calibration
was evaluated using the Hosmer-Lemeshow test for the goodness-of-fit sta-
tistic. The results are reported as odds ratios with 95% confidence intervals
and the relevant P value. Survival estimates and freedom from acute graft
rejection at follow-up were calculated using the Kaplan-Meier product-
limit method.RESULTS
Preoperative Patient Characteristics
Since August 2008, 46 patients have undergone trans-
plantation with CPB support, and, since February 2010,
an additional 46 patients have undergone transplantation
with ECMO support.
The ECMO group had a greater prevalence of pulmonary
hypertension as the indication for transplantation, admis-
sion to the ICU before transplantation, a preoperative
need for venoarterial ECMO support as a bridge to lungdiovascular Surgery c Volume 144, Number 6 1511
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Xtransplantation, and, hence, a greater preoperative risk of
PGD and mortality after lung transplantation.15,16 In
contrast, the CPB patients had a lower forced expiratory
volume in 1 second, which could have been related to the
greater prevalence of chronic obstructive pulmonary
disease (COPD) (Table 1).
During the study period, the following changes in trans-
plant management were introduced at our institution: (1)TABLE 1. Preoperative patient characteristics
Variable
CPB
(n ¼ 46)
ECMO
(n ¼ 46)
P
value
Female gender 18 (39) 26 (56) .09
Age (y) 42.6  16.7 42.8  14.4 .95
Chronic renal failure 8 (17) 7 (15) .78
Blood group
A 21 (46) 23 (50) .68
B 6 (13) 7 (15) .76
AB 2 (4) 1 (2) .55
O 17 (37) 15 (33) .66
CMV risk
Low 10 (22) 6 (13) .27
Intermediate 26 (56) 29 (63) .52
High 10 (22) 11 (24) .80
Listing grade
Elective 6 (10) 5 (11) .75
Urgency 11 (24) 7 (15) .29
High urgency 29 (63) 34 (74) .26
Pathologic entity
COPD 6 (13) 1 (2) .11
Pulmonary fibrosis 17 (37) 16 (34) .83
Cystic fibrosis 7 (15) 6 (13) .76
Pulmonary hypertension 5 (11) 17 (37) .003
Retransplantation 9 (20) 3 (7) .06
Other 2 (4)* 3 (7)y .50
Systolic pulmonary artery
pressure (mm Hg)
58  32 71  34 .08
FEV1 (% predicted) 36  22 49  25 .02
FVC1 (% predicted) 42  19 55  29 .09
6-min Walk test (m) 212  15 233  115 .48
Preoperative invasive mechanical
ventilation
5 (11) 4 (9) .50
Preoperative ICU stay 6 (13) 14 (30) .04
Preoperative ECMO/iLA
iLA 2 (4) 0 .49
Venovenous 3 (6) 4 (9) .64
Venoarterial 1 (2) 8 (17) .03
Donor
Female gender 27 (59) 25 (54) .67
Age (y) 39.7  14.3 41.5  14.4 .56
Ventilation (d) 6.1  3.8 5.1  4.1 .28
pO2 (100%) 377.3  125.2 392.7  124.8 .61
Data presented as mean  SD or n (%). CPB, Cardiopulmonary bypass; ECMO, ex-
tracorporeal membrane oxygenation; CMV, cytomegalovirus; COPD, chronic ob-
structive pulmonary disease; FEV1, forced expiratory volume in 1 second; FVC1,
forced vital capacity in 1 second; iLA, interventional lung assistance with Novalung;
pO2, partial oxygen pressure. *Langerhans cell histiocytosis in 1 and acute respiratory
distress syndrome in 1. ySarcoidosis in 2 and acute respiratory distress syndrome in 1.
1512 The Journal of Thoracic and Cardiovascular Surintraoperative ECMO instead of CPB support; (2) postoper-
ative extension of intraoperative ECMO support; and (3)
‘‘awake’’ ECMO as a bridge to transplantation.8 The post-
transplant immunosuppressive therapy regimen was similar
in the CPB and ECMO groups and was based on a triple-
drug regimen (calcineurin inhibitor, mycophenolate mofe-
til, which in some patients was switched to mammalian
target of rapamycin inhibitor beyond postoperative week
4, and prednisolone) without any induction therapy.
Operative Data
The indications for CPB/ECMO implantation were not
different between the CPB and ECMO patients and were
categorized as either preoperatively planned for patients
with pulmonary hypertension as an indication for transplan-
tation, ECMO as a bridge to transplantation, suprasystemic
systolic pulmonary pressure associated with the primary
lung disease, and need for a cardiac surgery procedure or
unplanned. In the latter case, the decision to use CPB/
ECMO support was taken intraoperatively, and implanta-
tion was elective if hemodynamic or respiratory instability
ensued after test clamping of the right pulmonary artery at
the beginning of the transplant procedure. It was considered
not elective, if, although the initial clamping of the right
pulmonary artery had not provoked any hemodynamic
and respiratory consequences, instability ensued later dur-
ing transplantation.
More ECMO implants were planned (P ¼ .004) owing to
the greater prevalence of pulmonary hypertension and preop-
erative ECMO. More CPB patients required a bilateral thor-
acosternotomy (clamshell) approach (P< .001; Table 2).
In contrast to the CPB patients, of whom 45 (98%) were
weaned intraoperatively from CPB support, only 27
ECMO patients (59%) were weaned intraoperatively from
ECMO (P< .01). The remaining 19 patients (41%) (12
with pulmonary hypertension, 4 with pulmonary fibrosis
and sarcoidosis with associated pulmonary hypertension,
and 1 each with retransplantation, cystic fibrosis, and acute
respiratory distress syndrome) were transferred to the ICU
with ECMO support (Figure 1).
Intraoperatively, the CPB patients required more packed
red blood cell (PRBC) transfusions (median, 10 U; range, 0-
58), platelet concentrates (median, 2; range, 0-7) than did
the ECMO patients. Overall, the patients who underwent
transplantation with a clamshell approach required more
PRBC transfusions and platelet concentrates (P ¼ .047
and P ¼ .017, respectively).
Postoperative Complications
Postoperative morbidity was greater in the CPB than in
the ECMO groups (Table 3). Of the CPB patients, 12
(26%) required secondary ECMO/iLA implantation, 18 
32 days (median, 2; range, 1-104) after lung transplantation.
Secondary ECMO/iLA implantation was required for acutegery c December 2012
TABLE 2. Intraoperative data
Variable
CPB
(n ¼ 46)
ECMO
(n ¼ 46)
P
value
Approach
Minimally invasive 21 (46) 36 (78) .01
Clamshell 24 (52) 10 (22) <.01
Planned CPB/ECMO implant 13 (28) 28 (61) .004
Nonelective CPB/ECMO implant 14 (30) 10 (22) .31
Single lung 5 (11) 4 (9) .72
Double lung 41 (89) 42 (91) .72
Postoperative va ECMO 1 (2) 19 (41) <.01
Lung volume reduction 12 (26) 8 (17) .31
Associated cardiac procedures 3 (6) 2 (4) .64
CABG 0 1 (2)
Aortic valve replacement 1 (2) 0
Tricuspid valve repair 1 (2) 0
Atrial septal defect 1 (2) 0
Patent foramen ovale 0 1 (2)
Ischemic time (min)
Left 518.0  151.7 581.4  140.3 .05
Right 431.9  140.3 450.2  135.7 .55
Single 495.4  150.3 400.0  125.5 .34
CPB time (min) 162  56
Intraoperative blood products
PRBCs (U) 12.2  10.9 7.1  8.6 .02
PC (U) 2.5  1.6 1.5  1.0 <.01
FFP (U) 7.2  6.4 7.1  7.8 .93
Fibrinogen (g) 2.09  1.9 1.6  1.5 .18
Prothrombin complex
concentrate (U)*
4.0  4.1 3.7  3.4 .70
Recombinant factor VIIa (U)y 0.1  0.4 0.0  0.0 .02
Data presented as mean  SD or n (%). CPB, Cardiopulmonary bypass; ECMO, ex-
tracorporeal membrane oxygenation; CABG, coronary artery bypass grafting;
PRBCs, packed red blood cells; PC, platelet concentrate; FFP, fresh frozen plasma.
*One unit equaled 500 UI. yOne unit equaled 60,000 UI.
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days (range, 35-104) after transplantation or for primary
graft dysfunction (iLA in 2 and venoarterial ECMO in 7)
2  2 days (range, 1-7) after transplantation. After
a mean ECMO/iLA support duration of 12  10 days, 10
patients could not be weaned from ECMO/iLA and died un-
der support, 1 patient was weaned but died 2 months later,
and 1 patient was successfully weaned and discharged 3
months later. Moreover, of these 12 CPB patients, 11 re-
quired dialysis.
In contrast, of the 19 primary ECMO patients, who had
been transferred to the ICU with ECMO support, 17
(89%) were successfully weaned from ECMO after 5 
3 days and survived until discharge, 1 patient was success-
fully weaned from ECMO but died of sepsis in-hospital 2
months later, and 1 patient died of PGD under ECMO sup-
port. Of the 27 primary ECMO patients, who had been
weaned from ECMO intraoperatively, only 2 (8%),
who had undergone transplantation early in 2010 for
pulmonary hypertension, required secondary ECMOThe Journal of Thoracic and Carimplantation because of recurrent lung edema after extu-
bation. Both patients were successfully weaned from
ECMO support, were discharged, and survived to the
last follow-up date (Figure 1).
Of the ECMO patients, 5 (11%) experienced complica-
tions related to percutaneous cannulation of the femoral
vessels (arteriovenous fistula in 2, type B dissection in 1,
and lower limb ischemia requiring embolectomy in 2).
Survival and Follow-up
Of the CPB patients, 18 (39%) died in-hospital (graft
dysfunction in 11, sepsis in 5, stroke in 1, and small cell
lung carcinoma in 1). In contrast, 6 ECMO patients
(13%) died in-hospital (graft dysfunction in 1, sepsis in 4,
and lung carcinoma in 1; P ¼ .004). Including the propen-
sity score for ECMO selection, multivariate analysis identi-
fied the following independent risk factors for in-hospital
death: retransplantation (odds ratio, 7.0; 95% confidence
interval, 1-43; P ¼ .034); transplantation with CPB support
(odds ratio, 4.9; 95% confidence interval, 1.2-20; P¼ .026;
Hosmer-Lemeshow statistic, P ¼ .7).
For the patients surviving at hospital discharge, the mean
follow-up was 18 11months (range, 3-40). At 3, 9, and 12
months, the freedom from acute rejection was 89%  6%
versus 67%  7%, 75%  8% versus 55%  8%, and
55%  10% versus 51%  9% in the CPB and ECMO
groups, respectively (P ¼ .12). The forced expiratory vol-
ume in 1 second (percentage of predicted) at discharge
and at the last follow-up visit was 51  13 versus 54% 
16% (P ¼ .45) and 59%  24% versus 61%  21%
(P ¼ .77) in the CPB and ECMO patients, respectively.
Six late deaths occurred, four in the CPB group (dissem-
inated aspergillosis, pneumonia, aortic valve endocarditis,
and post-transplant lymphoproliferative disorder in one
each) and two in the ECMO group (cardiomyopathy of un-
known origin and massive gastrointestinal bleeding in one
each). At 3, 9, and 12 months, overall survival was 70%
 7% versus 87%  5%, 59%  7% versus 81% 
6% and 56%  7% versus 81%  6% in the CPB and
ECMO patients, respectively (P ¼ .004; Figure 2). In con-
trast, survival conditional to hospital discharge was not dif-
ferent between the 2 groups (96%  3% vs 97%  3%,
96%  3% vs 94%  4%, and 93%  5% vs 94% 
4% in the CPB and ECMO patients, at 3, 9, and 12 months,
respectively; P ¼ .42). No difference was seen in survival
among the CPB and ECMO patients if only patients under-
going nonelective CPB/ECMO implantation (P ¼ .18) or
with COPD, cystic fibrosis, and pulmonary fibrosis as an in-
dication for transplantation (P ¼ .12) were considered.
At 3, 9, and 12 months, survival of the off-pump patients
was 96%  1%, 91%  2%, and 88%  2%, respec-
tively, and was similar to the survival of the ECMO patients
(P ¼ .26) and better than the survival of the CPB patients
(P<.001).diovascular Surgery c Volume 144, Number 6 1513
FIGURE 1. Detailed summary of patients undergoing lung transplantation with extracorporeal membrane oxygenation (ECMO) or cardiopulmonary
bypass (CPB) support at our institution. va, Venoarterial; LTx, lung transplantation; ICU, intensive care unit; iLA, interventional lung assistance with
NovaLung; vv, venovenous.
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Using ECMO instead of CPB for lung transplantation
was associated with lower mortality and morbidity, with
1-year survival comparable to that reported by the Interna-
tional Society for Heart and Lung Transplantation Registry
(81% in our ECMO patients and 79% in the International
Society for Heart and Lung Transplantation Registry), de-
spite the greater preoperative morbidity in the ECMO
group.17 Pulmonary hypertension and preoperative ECMO
support are well-recognized preoperative risk factors for
mortality in lung transplantation.5,15,16 On multivariate
analysis, lung transplantation with CPB support and
retransplantation, represented an independent risk factor
for in-hospital mortality.
These results have validated our new approach and further
confirm the pivotal role of ECMO in the pre-, intra-, and
postoperative management of patients requiring lung trans-
plantation. Although ECMO or iLA have already been dem-
onstrated to be valuable procedures as a bridge to lung
transplantation and as postoperative rescue therapy,6-10 the
role of ECMO for intraoperative cardiopulmonary support
has not yet been widely investigated,11-13,18 and CPB
remains the standard for intraoperative cardiopulmonary
support during lung transplantation.1 Aigner and col-
leagues12 found shorter ICU and hospital stays and better
survival rates with ECMO than with CPB. However, they
used ECMO as their routine approach for cardiopulmonary
support and resorted to CPB only if a concomitant cardiac
procedure was planned. Thus, more severely ill patients
were clustered in the CPB group.12 Bittner and colleagues18
reported a greater need for PRBC transfusions, longer oper-
ative times, a greater incidence of graft ischemia/reperfusion1514 The Journal of Thoracic and Cardiovascular Surinjury, and reduced 1-year survival in the ECMOgroup com-
pared with the CPB group. However, the results could have
been confounded by the relatively small case series
(8 ECMOand 7CPB patients) and by the absence of patients
needing retransplantation or preoperative ECMO support.18
In contrast, the influence of a patient selection bias was sig-
nificantly reduced in our study, because the decision to use
CPB or ECMO was not based on differences in the indica-
tion for surgery and was not made by the surgeon in charge
but resulted from a unanimous decision to change the cardio-
pulmonary support strategy in February 2010.
The pros and cons of CPB support during lung transplan-
tation and its prognostic effect on postoperative outcomes
have been widely discussed during previous years.4,19
Excellent survival results were reported in low-risk
elective patients with COPD or cystic fibrosis,20-22 with
hemodynamic and immunologic protective effects.19,21 In
contrast, 1-year survival rates similar to ours in CPB case
series of patients with pulmonary hypertension have been
reported,23-25 and CPB was even identified as a risk
factor for PGD.4,23 Regarding the potential mechanisms
explaining the negative outcome of CPB patients, of
major importance could have been the greater need for
blood transfusions in the CPB than in the ECMO patients,
which had already been associated with transfusion-
related lung injury and PGD.5 The lower blood product
use in ECMO patients, which compared favorably to previ-
ous CPB and off-pump case series,18,20 could have resulted
from the reduced heparin dose, which allowed better control
of hemostasis compared with CPB. The negative effect of
CPB on blood product use and the postoperative outcomes
could have been confounded by the greater prevalence ofgery c December 2012
FIGURE 2. Overall survival was worse for cardiopulmonary bypass
(CPB) than for extracorporeal membrane oxygenation (ECMO) patients
(P ¼ .004), especially because of greater early (in-hospital) mortality of
CPB patients.
TABLE 3. Postoperative data
Variable
CPB
(n ¼ 46)
ECMO
(n ¼ 46)
P
value
Rethoracotomy for bleeding 16 (35) 9 (19) .10
New requirement for dialysis 22 (48) 6 (13) <.01
Vascular complications 1 (2) 5 (11) .20
PGD score grade 3 9 (21)* 7 (15) .45
Atrial fibrillation 11 (24) 12 (26) .81
Rejection 18 (39) 15 (33) .51
Stroke 1 (2) 2 (4) .50
Superficial secondary wound
infection
6 (13) 7 (15) .76
Secondary ECMO/iLA implantation 12 (26) 2 (4) <.01
Tracheotomy 22 (48) 17 (37) .29
Ventilation time (d)y 21.4  28.8 14.1  19.1 .40
ICU stay (d)y 28.9  32.1 19.1  18.4 .46
Postoperative blood products
PRBC (U) 17.9  19.9 12.7  22.8 .26
PC (U) 4.8  8.8 3.3  5.8 .35
FFP (U) 17.6  34.8 11.1  25.8 .32
Fibrinogen (g) 0.6  2.2 0.5  1.7 .78
Prothrombin complex concentrate
(U)z
1.3  3.8 2.7  6.9 .24
Recombinant factor VIIa (U)x 0.02  0.14 0.02  0.151 .97
Spirometry at discharge
(% predicted)
VC (L) 49  13 52  15 .37
FEV1 (L) 51  13 54  16 .45
FEF 50% (L/s) 64  28 65  26 .83
FEF 25% (L/s) 76  41 71  41 .67
FEF 25%-75% (L/s) 71  28 70  29 .96
Data presented as mean  SD or n (%). CPB, Cardiopulmonary bypass; ECMO, ex-
tracorporeal membrane oxygenation; PGD, primary graft dysfunction; iLA, interven-
tional lung assist Novalung; ICU, intensive care unit; PRBCs, packed red blood cells;
PC, platelet concentrate; FFP, fresh frozen plasma; VC, vital capacity; FEV1, forced
expiratory volume in 1 second; FEF, forced expiratory flow. *Data not available for 4
patients (9%). yICU survival (patients who died30 days were censored). zOne unit
equaled 500 U. xOne unit equaled 60,000 UI.
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patients. In the former case, no significant difference was
seen among the CPB patients who required a clamshell or
minimally invasive approach regarding intra- and
postoperative PRBC, platelet concentrate, and fresh
frozen plasma use. In the latter case, the greater heparin
dose in the CPB patients could have eventually worsened
the diffuse bleeding from pleural adhesions. Moreover, the
negative effect of retransplantation on in-hospital mortality
was distributed equally among the CPB and ECMO pa-
tients, with no difference between the retransplanted CPB
and ECMO patients (P ¼ .8).
CPB seems to allow for less-versatile postoperative hemo-
dynamic management, especially in patients with pulmonary
hypertension,who are at high risk of developing PGDpostop-
eratively.5,15,16 This was reflected by the greater need for
secondary ECMO/iLA implant in the CPB than ECMO
patients in our case series. Of the 9 CPB patients who
required a secondary ECMO/iLA implant for PGD, 6 hadThe Journal of Thoracic and Carpresented preoperatively with pulmonary hypertension.
In addition, all these patients developed acute renal failure,
and 8 patients required dialysis. Extending ECMO support
postoperatively, instead, allowed the blood flow to adapt to
the pulmonary bed and at the same time to optimize
the ventilatory and fluid management strategy by avoiding
high inspiratory pressures and hemodynamic instability
and eventually barotrauma and dialysis. Thus, only
2 ECMO patients required secondary ECMO implantation
for delayed graft dysfunction. Both had undergone
transplantation for pulmonary hypertension in February
2010 at the beginning of our experience with ECMO, and
in both patients, ECMO support was initially not
extended postoperatively. However, we now transfer
patients with pulmonary hypertension as the indication for
transplantation from the operating room to the ICU with
continuous ECMO support. Such patients will not be
weaned until they are fully awake and extubated. Extending
ECMO support postoperatively should no longer be
regarded as a complication. In contrast, it should be
considered a fundamental part of a management strategy
that, during the past 3 years, has led to increasing
enthusiasm to perform double lung transplantation in
patients with pulmonary hypertension (3% in 2008, 2% in
2009, 10% in 2010, and 6% in 2011) and to greatly reduce
in 2011 the need for secondary ECMO implantation overall
(1 [0.8%] of 125 patients).
Finally, ECMOmight reduce the proinflammatory effects
of CPB, which have already been demonstrated in cardiac
surgery to provoke a systemic inflammatory response.2-4
This advantage could result from the centrifugal, instead
of roller, pumps, which reduce the risk of hemolysis,2 the
shorter tubing system, and avoidance of cardiotomy suction
systems and venous reservoirs with their air–blood inter-
face. Thus, ECMO reduces the risk of the development ofdiovascular Surgery c Volume 144, Number 6 1515
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Xsystemic inflammatory response and, because it does not re-
quire full heparinization, the risk of bleeding and the subse-
quent need for transfusion.
Study Limitations
The following study limitations were identified. First, this
was a retrospective single-center study. Second, the results
could have been flawed by the poor outcomes of the CPB pa-
tients. However, because most lung transplants at our insti-
tution are performed without CPB or ECMO, CPB was
only used in those patients that absolutely required it for he-
modynamic and respiratory reasons, causing a selection bias
toward patients with a greater preoperative risk than that of
patients with COPD and cystic fibrosis, in whom excellent
results with CPB have been demonstrated.20-22 However,
the greater preoperative risk profile of the ECMO patients
compared with that of the CPB patients should have
negatively influenced the outcome of the ECMO patients
and not that of the CPB patients. Third, the CPB patients
were transplanted before the ECMO patients in
a consecutive fashion. However, in contrast to other CPB
series,20-22 the study period consisted of a relatively short
period (3 years), with a greater incidence of patients
transplanted monthly (2 patient/mo and 2.5 patients/mo
for the CPB and ECMO groups, respectively) and with an
otherwise unchanged overall transplant protocol. The
clamshell approach was used less often in the ECMO
group than in the CPB group, in part because cannulation
for ECMO was routinely performed in the groin, which
did not necessitate opening the pericardium. Postoperative
bleeding could thus have been reduced by the minimally
invasive incisions, potentially confounding the results.
Because this confounder was, however, itself caused by
the change from CPB to ECMO, it could be regarded as
another advantage of our ECMO strategy.
CONCLUSIONS
Compared with the CPB patients, the ECMO patients
showed better survival and a better postoperative course.
ECMO versatility, which allows pre-, intra-, and postopera-
tive support, permits successful treatment of unstable
patients, such as those with primary pulmonary hyperten-
sion. For these reasons, it has become our new standard of
care in lung transplantation, instead of CPB, which could
have a very limited role in highly selected patients who
require concomitant open heart surgery.
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